United States Drug Enforcement Administration

WASHINGTON – The Drug Enforcement Administration will host public listening sessions to receive comments from healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine.

The listening sessions will be held in person and livestreamed with remote participation available.

WHAT:                       Public Listening Sessions on Telemedicine Regulations

WHO:                         Open to the public                                

WHEN:                       September 12-13, 2023

WHERE:                     DEA Headquarters

                                    700 Army Navy Drive

                                    Arlington, Va. 22202

Note: Registration for members of the public to attend in person or make oral presentations has now closed. The event will be livestreamed and publicly available.

FOR NEWS MEDIA: News media wishing to attend in person must RSVP to DEA.Public.Affairs@dea.gov by 5 p.m. on September 11, 2023.  Members of the media should arrive no later than 8 a.m. on September 12 and 13 for setup.

For more information, visit Federal Register: Practice of Telemedicine: Listening Sessions.

For additional questions, email DPW@DEA.gov   

Background:

On March 1, 2023, DEA, in concert with the Department of Health and Human Services (HHS), issued notices of proposed rulemakings (NPRM) to allow for prescribing of certain controlled medications via telemedicine without an in-person medical evaluation of the patient under circumstances that are consistent with public health, safety, and effective controls against diversion. On May 9, DEA and HHS announced the extension of COVID-19 telemedicine flexibilities for an additional six months while considering the more than 38,000 comments from the public on the NPRMs.

# # #